Donald Trump's renewed push to take control of Greenland is setting off a high-stakes showdown with Denmark, a small country ...

An advocacy group that includes the main pharmaceutical lobbying organization, PhRMA, as a member is complaining that a commercial Hims & Hers Health (NYSE:HIMS) is slated to run during the Super Bowl ...

In its outlook for 2025, Novo Nordisk has predicted 'continued periodic supply constraints and related drug shortage ...

The Danish maker of Ozempic and Wegovy reported a 25 percent increase in sales to $40.6 billion, but said it expected slower ...

Obesity drug maker Novo Nordisk forecast slower growth this year after Wegovy sales more than doubled in the fourth quarter, ...

Novo Nordisk shares rose 4.5% after a strong Q4 profit beat, driven by high demand for obesity drug Wegovy, despite forecasting slower sales growth for 2025.

Danish pharmaceutical behemoth Novo Nordisk on Wednesday reported better-than-expected net profit in the fourth quarter, amid ...

Investors are upset at a lack of clarity over the results of Wegovy successor CagriSema after trials published in December.

Telehealth company Hims & Hers' first Super Bowl ad is provocative and effective in building awareness of its weight loss ...

A new study examines how cost, side effects, and other factors influence whether people stop GLP-1s, while Noom cuts staff to ...